Q-omics provides the consensus-scored DEFB112 profile across patient tissues and cancer cell-line models. DEFB112 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in BLCA. Additionally, DEFB112 RNA expression shows 12,079 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight BLCA, and COAD as cancer lineages where DEFB112 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEFB112 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEFB112 survival associations across molecular data types. DEFB112 RNA expression shows survival associations in the most cancer types (9), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEFB112 RNA expression–survival associations across cancer types. High DEFB112 expression shows unfavorable associations in BLCA, UCEC, KIRC, KIRP and BRCA, but favorable associations in SCLC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for DEFB112 RNA expression.
This table shows molecular features associated with DEFB112 in patient tissues and cancer cell lines. In patient samples, DEFB112 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set. In cancer cell lines, DEFB112 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
